Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VB 201

Next Previous
X
Search
Drug Profile

VB 201

Alternative Names: CI-201; VB-201

Latest Information Update: 07 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VBL Therapeutics
  • Developer Notable Labs
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Phospholipids; Small molecules
  • Mechanism of Action CD14 antigen inhibitors; Cell movement inhibitors; Interleukin 12 subunit p40 inhibitors; Phospholipid modulators; Toll-like receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atherosclerosis; COVID 2019 infections
  • No development reported Hepatic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Non-alcoholic fatty liver disease; Renal fibrosis; Rheumatoid arthritis
  • Discontinued Plaque psoriasis; Ulcerative colitis

Most Recent Events

  • 25 Oct 2022 VBL Therapeutics completes a phase II trial for COVID-2019 infections in Israel (PO) (NCT04733833)
  • 28 Sep 2022 No recent reports of development identified for preclinical development in Renal-fibrosis in Israel (PO, Capsule)
  • 25 Jun 2021 University of California plans a phase I/II VITAL HIV trial in Inflammation (in treated HIV) in USA (PO, Tablet) in July 2022 (NCT04939311)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top